Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells

Cancer Immunology, Immunotherapy

Volumn 60, Issue 4, 2011, Pages 575-586

  Buddingh, Emilie P ^a   Schilham, Marco W ^a   Ruslan, S Eriaty N ^a   Berghuis, Dagmar ^a   Szuhai, Karoly ^a   Suurmond, Jolien ^a   Taminiau, Antonie H M ^a   Gelderblom, Hans ^a   Egeler, R Maarten ^a   Serra, Massimo ^b   Hogendoorn, Pancras C W ^a   Lankester, Arjan C ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Bone sarcoma; Immunotherapy; NK cells; Osteosarcoma

Indexed keywords

BETA 2 MICROGLOBULIN; CISPLATIN; DNAX ACCESSORY MOLECULE 1; DOXORUBICIN; HLA A ANTIGEN; HLA ANTIGEN CLASS 1; HLA B ANTIGEN; HLA C ANTIGEN; INTERLEUKIN 15; INTERLEUKIN 2; METHOTREXATE; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2D; UNCLASSIFIED DRUG;

ALLOGRAFT; ARTICLE; AUTOGRAFT; CANCER CELL CULTURE; CELL ACTIVATION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY TEST; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; NATURAL KILLER CELL; OSTEOSARCOMA; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION;

ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; BONE NEOPLASMS; CELL SEPARATION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-15; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; OSTEOSARCOMA; TISSUE ARRAY ANALYSIS;

EID: 79953805065     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0965-3     Document Type: Article

References (46)

1. Klein MJ, Parisien MV, Schneider-Stock R (2002) Osteogenic Tumours. In: Fletcher CDM, Unni KK, Mertens F (eds) World health classification of tumours. Pathology and genetics of tumours of soft tissue and bone. IARC Press, Lyon, pp 259-285
2. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, Zoubek A, Jurgens H, Winkler K (2002) Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776-790 (Pubitemid 34111386)
3. Buddingh EP, Anninga JK, Versteegh MI, Taminiau AH, Egeler RM, van Rijswijk CS, Hogendoorn PCW, Lankester AC, Gelderblom H (2010) Prognostic factors in pulmonary metastasized high-grade osteosarcoma. Pediatr Blood Cancer 54:216-221
4. Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PCW, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, Kirkpatrick A, Hauben EI, Craft AW, Taminiau AHM (2007) Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 99:112-128
5. Marina N, Bielack S, Whelan J, Smeland S, Krailo M, Sydes MR, Butterfass-Bahloul T, Calaminus G, Bernstein M (2009) International collaboration is feasible in trials for rare conditions: the EURAMOS experience. Cancer Treat Res 152:339-353
6. Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, Conrad E, Ferguson W, Gebhardt M, Goorin AM, Harris MB, Healey J, Huvos A, Link M, Montebello J, Nadel H, Nieder M, Sato J, Siegal G, Weiner M, Wells R, Wold L, Womer R, Grier H (2005) Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 23:2004-2011 (Pubitemid 46211380)
7. Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, Ferguson WS, Gebhardt MC, Goorin AM, Harris M, Kleinerman E, Link MP, Nadel H, Nieder M, Siegal GP, Weiner MA, Wells RJ, Womer RB, Grier HE (2008) Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival - a report from the Children's Oncology Group. J Clin Oncol 26:633-638 (Pubitemid 351264359)
8. Terme M, Ullrich E, Delahaye NF, Chaput N, Zitvogel L (2008) Natural killer cell-directed therapies: moving from unexpected results to successful strategies. Nat Immunol 9:486-494 (Pubitemid 351560517)
9. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB (2005) Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 105:3051-3057
10. Ljunggren HG, Malmberg KJ (2007) Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol 7:329-339
11. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, Biassoni R, Moretta L (2001) Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 19:197-223 (Pubitemid 32368034)
12. Mistry AR, O'Callaghan CA (2007) Regulation of ligands for the activating receptor NKG2D. Immunology 121:439-447 (Pubitemid 47030096)
13. Verhoeven DH, de Hooge AS, Mooiman EC, Santos SJ, ten Dam MM, Gelderblom H, Melief CJ, Hogendoorn PCW, Egeler RM, van Tol MJ, Schilham MW, Lankester AC (2008) NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol Immunol 45:3917-3925
14. Lakshmikanth T, Burke S, Ali TH, Kimpfler S, Ursini F, Ruggeri L, Capanni M, Umansky V, Paschen A, Sucker A, Pende D, Groh V, Biassoni R, Hoglund P, Kato M, Shibuya K, Schadendorf D, Anichini A, Ferrone S, Velardi A, Karre K, Shibuya A, Carbone E, Colucci F (2009) NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J Clin Invest 119:1251-1263
15. Bottino C, Castriconi R, Pende D, Rivera P, Nanni M, Carnemolla B, Cantoni C, Grassi J, Marcenaro S, Reymond N, Vitale M, Moretta L, Lopez M, Moretta A (2003) Identification of PVR (CD155) and nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 198:557-567 (Pubitemid 37040390)
16. El-Sherbiny YM, Meade JL, Holmes TD, McGonagle D, Mackie SL, Morgan AW, Cook G, Feyler S, Richards SJ, Davies FE, Morgan GJ, Cook GP (2007) The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res 67:8444-8449
17. Karre K (2008) Natural killer cell recognition of missing self. Nat Immunol 9:477-480
18. Berghuis D, de Hooge ASK, Santos SJ, Horst D, Wertz EJ, van Eggermond MC, van den Elsen PJ, Taminiau AHM, Ottaviano L, Schaefer KL, Dirksen U, Hooijberg E, Mulder A, Melief CJM, Egeler RM, Schilham MW, Jordanova ES, Hogendoorn PCW, Lankester AC (2009) Reduced human leukocyte antigen expression in advanced-stage Ewing sarcoma: implications for immune recognition. J Pathol 218:222-231
19. Chang CC, Ferrone S (2007) Immune selective pressure and HLA class I antigen defects in malignant lesions. Cancer Immunol Immunother 56:227-236
20. Mohseny AB, Szuhai K, Romeo S, Buddingh EP, Briaire-de Bruijn I, de Jong D, van Pel M, Cleton-Jansen AM, Hogendoorn PCW (2009) Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2. J Pathol 219:294-305
21. Ottaviano L, Schaefer KL, Gajewski M, Huckenbeck W, Baldus S, Rogel U, Mackintosh C, de Alava E, Myklebost O, Kresse SH, Meza-Zepeda LA, Serra M, Cleton-Jansen AM, Hogendoorn PCW, Buerger H, Aigner T, Gabbert HE, Poremba C (2010) Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosomes Cancer 49:40-51
22. Pasello M, Michelacci F, Scionti I, Hattinger CM, Zuntini M, Caccuri AM, Scotlandi K, Picci P, Serra M (2008) Overcoming glutathione S-transferase P1-related cisplatin resistance in osteosarcoma. Cancer Res 68:6661-6668
23. Serra M, Reverter-Branch MauriciD, Benini S, Shen JN, Chano T, Hattinger CM, Manara MC, Pasello M, Scotlandi K, Picci P (2004) Analysis of dihydrofolate reductase and reduced folate carrier gene status in relation to methotrexate resistance in osteosarcoma cells. Ann Oncol 15:151-160 (Pubitemid 38145532)
24. Serra M, Scotlandi K, Manara MC, Maurici D, Lollini PL, Degiovanni C, Toffoli G, Baldini N (1993) Establishment and characterization of multidrug-resistant human osteosarcoma cell-lines. Anticancer Res 13:323-329 (Pubitemid 23196764)
25. Szuhai K, Ijszenga M, Tanke HJ, Rosenberg C, Hogendoorn PCW (2006) Molecular cytogenetic characterization of four previously established and two newly established Ewing sarcoma cell lines. Cancer Genet Cytogenet 166:173-179
26. Ruiter DJ, Ferrier CM, van Muijen GNP, Henzen-Logmans SC, Kennedy S, Kramer MD, Nielsen BS, Schmitt M (1998) Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. Eur J Cancer 34:1334-1340 (Pubitemid 28370922)
27. Cho D, Shook DR, Shimasaki N, Chang YH, Fujisaki H, Campana D (2010) Cytotoxicity of activated natural killer cells against pediatric solid tumors. Clin Cancer Res 16:3901-3909
28. Nakashima Y, Deie M, Yanada S, Sharman P, Ochi M (2005) Magnetically labeled human natural killer cells, accumulated in vitro by an external magnetic force, are effective against HOS osteosarcoma cells. Int J Oncol 27:965-971
29. Liebau C, Merk H, Schmidt S, Roesel C, Karreman C, Prisack JB, Bojar H, Baltzer AWA (2002) Interleukin-12 and interleukin-18 change ICAM-1 expression, and enhance natural killer cell mediated cytolysis of human osteosarcoma cells. Cytokines Cell Mol Ther 7:135-142 (Pubitemid 37531601)
30. Honorati MC, Neri S, Cattini L, Facchini A (2003) IL-17 enhances the susceptibility of U-2OS osteosarcoma cells to NK cell lysis. Clin Exp Immunol 133:344-349 (Pubitemid 37046957)
31. Kubista B, Trieb K, Blahovec H, Kotz R, Micksche M (2002) Hyperthermia increases the susceptibility of chondro- and osteosarcoma cells to natural killer cell-mediated lysis. Anticancer Res 22:789-792 (Pubitemid 34475229)
32. Mariani E, Tarozzi A, Meneghetti A, Tadolini M, Facchini A (1996) Lytic activity of IL-2 and IL-12 stimulated NK cells against HOS osteosarcoma cell line. Boll Soc Ital Biol Sper 72:21-27
33. Mariani E, Tarozzi A, Meneghetti A, Cattini L, Facchini A (1997) Human osteosarcoma cell susceptibility to natural killer cell lysis depends on CD54 and increases after TNF alpha incubation. FEBS Lett 406:83-88 (Pubitemid 27156963)
34. Mariani E, Tarozzi A, Meneghetti A, Cattini L, Facchini A (1998) TNF-alpha but not IL-1 and IL-6 modifies the susceptibility of human osteosarcoma cells to NK lysis. Int J Oncol 13:349-353 (Pubitemid 28329225)
35. Mariani E, Meneghetti A, Tarozzi A, Cattini L, Facchini A (2000) Interleukin-12 induces efficient lysis of natural killer-sensitive and natural killer-resistant human osteosarcoma cells: The synergistic effect of interleukin-2. Scand J Immunol 51:618-625 (Pubitemid 30353373)
36. Meneghetti A, Mariani E, Santi S, Riccio M, Cattini L, Paoletti S, Facchini A (1999) NK binding capacity and lytic activity depend on the expression of ICAM-1 on target bone tumours. Int J Oncol 15:909-914
37. Sottnik JL, U'ren LW, Thamm DH, Withrow SJ, Dow SW (2010) Chronic bacterial osteomyelitis suppression of tumor growth requires innate immune responses. Cancer Immunol Immunother 59:367-378
38. Luksch R, Perotti D, Cefalo G, Passerini CG, Massimino M, Spreafico F, Casanova M, Ferrari A, Terenziani M, Polastri D, Gambirasio F, Podda M, Bozzi F, Ravagnani F, Parmiani G, Bellani FF (2003) Immunomodulation in a treatment program including pre- and post-operative interleukin-2 and chemotherapy for childhood osteosarcoma. Tumori 89:263-268 (Pubitemid 37014116)
39. Chowdhury D, Lieberman J (2008) Death by a thousand cuts: granzyme pathways of programmed cell death. Annu Rev Immunol 26:389-420 (Pubitemid 351611623)
40. Screpanti V, Wallin RPA, Ljunggren HG, Grandien A (2001) A central role for death receptor-mediated apoptosis in the rejection of tumors by NK cells. J Immunol 167:2068-2073 (Pubitemid 32747514)
41. Gordon N, Koshkina NV, Jia SF, Khanna C, Mendoza A, Worth LL, Kleinerman ES (2007) Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin Cancer Res 13:4503-4510 (Pubitemid 47219720)
42. Gordon N, Arndt CAS, Hawkins DS, Dohero DK, Inwards CY, Munsell MF, Stewart J, Koshkina NV, Kleinerman ES (2005) Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol 27:611-615 (Pubitemid 41697350)
43. Koshkina NV, Khanna C, Mendoza A, Guan H, DeLauter L, Kleinerman ES (2007) Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res 5:991-999 (Pubitemid 350070755)
44. Konjevic G, Mirjacic MK, Vuletic A, Jovic V, Jurisic V, Babovic N, Spuzic I (2007) Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients. Clin Exp Metastasis 24:1-11 (Pubitemid 46569334)
45. Garcia-Iglesias T, del Toro-Arreola A, barran-Somoza B, del Toro-Arreola S, Sanchez-Hernandez PE, Ramirez-Duenas MG, Balderas-Pena LM, Bravo-Cuellar A, Ortiz-Lazareno PC, neri-Navarro A (2009) Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC Cancer 9:186
46. van Ostaijen-ten Dam M, Verhoeven D, Kraal K, Bongaerts R, van Bergen J, Ball LM, Lankester A, van Tol M, Zwaginga J (2010) Preclinical validation of an NK cell preparation: phenotype and function of NK cell products isolated via CliniMacs and subsequent ex vivo activation with IL-2 or IL-15. Bone Marrow Transplant 45:S302-S303